118 related articles for article (PubMed ID: 17292461)
1. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Crotzer DR; Sun CC; Coleman RL; Wolf JK; Levenback CF; Gershenson DM
Gynecol Oncol; 2007 May; 105(2):404-8. PubMed ID: 17292461
[TBL] [Abstract][Full Text] [Related]
2. Ovarian clear cell carcinoma with uterine intramural recurrence: Case report of ovarian clear cell carcinoma with fertility sparing treatment.
Chang TY; Yeh CY; Yang CY; Lin WC; Huang CC; Hung YC
Taiwan J Obstet Gynecol; 2024 Jan; 63(1):90-94. PubMed ID: 38216278
[TBL] [Abstract][Full Text] [Related]
3. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.
Gershenson DM; Sun CC; Iyer RB; Malpica AL; Kavanagh JJ; Bodurka DC; Schmeler K; Deavers M
Gynecol Oncol; 2012 Jun; 125(3):661-6. PubMed ID: 22406638
[TBL] [Abstract][Full Text] [Related]
4. Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary.
Tamada Y; Takeuchi H; Suzuki N; Susumu N; Aoki D; Irimura T
Cancer Sci; 2007 Oct; 98(10):1586-91. PubMed ID: 17711507
[TBL] [Abstract][Full Text] [Related]
5. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
Mabuchi S; Sugiyama T; Kimura T
J Gynecol Oncol; 2016 May; 27(3):e31. PubMed ID: 27029752
[TBL] [Abstract][Full Text] [Related]
6. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
Takano M; Sugiyama T; Yaegashi N; Sakuma M; Suzuki M; Saga Y; Kuzuya K; Kigawa J; Shimada M; Tsuda H; Moriya T; Yoshizaki A; Kita T; Kikuchi Y
Int J Gynecol Cancer; 2008; 18(5):937-42. PubMed ID: 18081792
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Sugiyama T; Okamoto A; Enomoto T; Hamano T; Aotani E; Terao Y; Suzuki N; Mikami M; Yaegashi N; Kato K; Yoshikawa H; Yokoyama Y; Tanabe H; Nishino K; Nomura H; Kim JW; Kim BG; Pignata S; Alexandre J; Green J; Isonishi S; Terauchi F; Fujiwara K; Aoki D
J Clin Oncol; 2016 Aug; 34(24):2881-7. PubMed ID: 27400948
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T
Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667
[TBL] [Abstract][Full Text] [Related]
9. Patterns of recurrence and impact on survival in patients with clear cell ovarian carcinoma.
Hogen L; Vicus D; Ferguson SE; Gien LT; Nofech-Mozes S; Lennox GK; Bernardini MQ
Int J Gynecol Cancer; 2019 Sep; 29(7):1164-1169. PubMed ID: 31273067
[TBL] [Abstract][Full Text] [Related]
10. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Oda K; Hamanishi J; Matsuo K; Hasegawa K
Gynecol Oncol; 2018 Nov; 151(2):381-389. PubMed ID: 30217369
[TBL] [Abstract][Full Text] [Related]
11. Evidence for ethnic and environmental contributions to frequency of ovarian clear cell carcinoma.
Tay SK; Cheong MA
Aust N Z J Obstet Gynaecol; 2014 Jun; 54(3):225-30. PubMed ID: 24888594
[TBL] [Abstract][Full Text] [Related]
12. Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma.
Kajiyama H; Shibata K; Mizuno M; Yamamoto E; Fujiwara S; Umezu T; Suzuki S; Nakanishi T; Nagasaka T; Kikkawa F
Int J Gynecol Cancer; 2012 Jun; 22(5):801-6. PubMed ID: 22617480
[TBL] [Abstract][Full Text] [Related]
13. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
14. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
Chan JK; Teoh D; Hu JM; Shin JY; Osann K; Kapp DS
Gynecol Oncol; 2008 Jun; 109(3):370-6. PubMed ID: 18395777
[TBL] [Abstract][Full Text] [Related]
15. Review the progression of ovarian clear cell carcinoma from the perspective of genomics and epigenomics.
Tong A; Di X; Zhao X; Liang X
Front Genet; 2023; 14():952379. PubMed ID: 36873929
[TBL] [Abstract][Full Text] [Related]
16. From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.
Liu Z; Jing C; Kong F
J Ovarian Res; 2024 Feb; 17(1):39. PubMed ID: 38347608
[TBL] [Abstract][Full Text] [Related]
17. Dual blockade of BRD4 and ATR/WEE1 pathways exploits
Kinose Y; Xu H; Kim H; Kumar S; Shan X; George E; Wang X; Medvedev S; Ferman B; Gitto SB; Whicker M; D'Andrea K; Wubbenhorst B; Hallberg D; O'Connor M; Schwartz LE; Hwang WT; Nathanson KL; Mills GB; Velculescu VE; Wang TL; Brown EJ; Drapkin R; Simpkins F
Res Sq; 2023 Sep; ():. PubMed ID: 37841875
[No Abstract] [Full Text] [Related]
18. Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series.
Calo CA; Levine MD; Brown MD; O'Malley DM; Backes FJ
Gynecol Oncol Rep; 2023 Apr; 46():101171. PubMed ID: 37065539
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
Gan M; Tai Z; Yu Y; Zhang C; Xu J
PeerJ; 2023; 11():e14653. PubMed ID: 36721777
[TBL] [Abstract][Full Text] [Related]
20. Frequency of thoracic recurrence based on pathological features in patients with ovarian epithelial tumors in stage I versus higher stages.
Matsutani H; Nakai G; Fujiwara S; Takahashi S; Yamamoto K; Ohmichi M; Osuga K
Jpn J Radiol; 2023 May; 41(5):500-509. PubMed ID: 36575285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
